Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
Brown, N McBain, Catherine A Nash, S Hopkins, K Sanghera, P Saran, F Phillips, M Dungey, F Clifton-Hadley, L Wanek, K
Brown, N
McBain, Catherine A
Nash, S
Hopkins, K
Sanghera, P
Saran, F
Phillips, M
Dungey, F
Clifton-Hadley, L
Wanek, K
Citations
Altmetric:
Abstract
Cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, failed to show benefit over lomustine in relapsed glioblastoma. One resistance mechanism for cediranib is up-regulation of epidermal growth factor receptor (EGFR). This study aimed to determine if dual therapy with cediranib and the oral EGFR inhibitor gefitinib improved outcome in recurrent glioblastoma.
Authors
Brown, N
McBain, Catherine A
Nash, S
Hopkins, K
Sanghera, P
Saran, F
Phillips, M
Dungey, F
Clifton-Hadley, L
Wanek, K
Krell, D
Jeffries, S
Khan, I
Smith, P
Mulholland, P
McBain, Catherine A
Nash, S
Hopkins, K
Sanghera, P
Saran, F
Phillips, M
Dungey, F
Clifton-Hadley, L
Wanek, K
Krell, D
Jeffries, S
Khan, I
Smith, P
Mulholland, P
Affiliation
University College London Hospitals, London
Description
Date
2016
Publisher
Collections
Keywords
Type
Article
Citation
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma. 2016, 11 (5):e0156369 PLoS ONE